Presbyopia Treatment Market Size is anticipated to Grow at a CAGR of 4% during the Study Period [2018-2030] | Delveinsight

April 06 00:11 2021
Presbyopia Treatment Market Size is anticipated to Grow at a CAGR of 4% during the Study Period [2018-2030] | Delveinsight

Presbyopia Treatment Market

DelveInsight’s “Presbyopia Market” report provides a thorough comprehension of the Presbyopia, historical and forecasted epidemiology, and the Presbyopia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Presbyopia market report also proffers an analysis of the current Presbyopia treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 

Some of the key takeaways of the Presbyopia Market Research Report

  • Findings from the secondary domain suggest that as many as 80% of the uncorrected presbyopes faced trouble performing near-vision-related tasks such as reading, writing, threading needles, and using mobile devices, which could impact patients’ productivity.
  • According to the WHO, 1.8 billion people globally were diagnosed with presbyopia in 2015 and cases are expected to reach 2.1 billion by 2030. In the US alone, around 120 million people are currently living with presbyopia. And cases are expected to increase in the future, opening a new window of opportunities for emerging therapies.
  • Currently, there are no FDA-approved drugs, and there is a high unmet need for new therapies for Presbyopia treatment. All current non-pharmacological treatment options are either inconvenient or invasive, posing a major unmet need for people with presbyopia to enhance the quality of life. There is a clear unmet need for effective, safe, comfortable, convenient, and easy-to-use therapies, which can also slow, halt or reverse the progression rate.
  • Recently, some developmental initiatives have been taken towards Presbyopia management as major key players such as Novartis AG, ORASIS Pharmaceuticals Ltd., Eyenovia, AbbVie, Regeneron Pharmaceuticals, Amgen, Ocuphire Pharma, Visus Therapeutics, and others have shown interest in developing therapies.
  • Potential therapies such as AGN-190584MicroLine (PilocarpineOphthalmic), Nyxol (Phentolamine Mesylate), PresbiDrops, VTI-001 (Brimochol), AGN-241622, UNR844, MicroLine, AGN-190584, AGN-241622, and several others are under clinical trials for investigating new Presbyopia treatment options. They will provide efficient therapeutic approaches with novel mechanisms of action to treat patients affected with Presbyopia.
  • Most of the current emerging therapies are based on the pilocarpine, which produces a “pinhole” effect for vision accommodation with the pupil’s constriction. As per our analysis, the FDA might slap warnings for these drugs on approval, limiting drugs usage in driving at night and operating heavy machinery, especially in poor light.

 

For further information on Market Impact by Therapies, visit: Presbyopia Treatment Market Trends 

 

Presbyopia is the gradual loss of near-focusing ability that occurs with age. Presbyopia is caused partly due to age-related changes in the proteins within the eye lens, due to which it becomes thicker, more challenging, and less flexible. This loss of flexibility affects the lens’s ability to refract light rays, which affects the eye’s capacity to focus.

Presbyopia mainly affects the age-group between 40 and 60 as the eyes’ lenses naturally lose elasticity due to the ageing process. According to DelveInsight’s analysts, the total Presbyopia prevalent cases in the 7MM were 286,994,105 cases in 2020. These cases are expected to grow with a nominal CAGR in the forecast period 2021–2030. 

 

The Presbyopia Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Total Presbyopia Prevalent Cases
  • Total Presbyopia Diagnosed Cases
  • Total Presbyopia Age-specific Cases
  • Presbyopia Gender-specific Cases
  • Presbyopia Severity-specific Cases
  • Total Presbyopia Treated cases

 

Get a sample copy of this report: Presbyopia Market Landscape

 

Presbyopia Treatment Market 

The Presbyopia treatment goal is to compensate for the inability of the eyes to focus on nearby objects. Currently, the market is mainly dominated by non-pharmacological treatment options such as corrective eyeglasses (spectacle lenses) or contact lenses, refractive surgery, or lens implants. Current clinical management of Presbyopia includes off-label treatment using nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The most commonly used agents are Pilocarpine, Carbachol, Aceclidine, Brimonidine, Nepafenac, and others.

Presbyopia pharmacological treatment is based on using ophthalmic drops for improving near vision. Many different modifications, including the combination of two parasympathomimetics and an NSAID, two parasympathomimetics and one parasympatholytic, carbachol 2.25% with brimonidine 0.2%, and a variety of pilocarpine 0.247%, phenylephrine 0.78%, polyethylene glycol 0.09%, nepafenac 0.023%, pheniramine 0.034%, and naphazoline 0.003% were studied. A different strategy based on lipoic acid derivative drops aims to soften the crystalline lens.

In the US and Europe, some tempering components of the drug formulation also used as an off-label treatment in Presbyopia are brimonidine to reduce ciliary muscle contraction, bromfenac, diclofenac, and dexamethasone to minimise inflammation and ciliary muscle contraction, phenylephrine to decrease ciliary muscle contraction, naphazoline to minimise redness, tropicamide to reduce accommodation, and polyethylene glycol to increase comfort. 

The companies have initiated clinical trials to investigate new treatment options and manage disease in the 7MM. 

 

 

Presbyopia Emerging Therapies Along with Key Players

  • AGN-190584: Allergan (acquired by AbbVie)
  • MicroLine (Pilocarpine Ophthalmic): Eyenovia
  • PresbiDrops (CSF-1): Orasis Pharmaceuticals
  • Nyxol (Phentolamine Mesylate): Ocuphire Pharma
  • UNR844 (Lipoic acid choline ester; formerly known as EV06): Novartis
  • VTI-001 (Brimochol): Visus Therapeutics
  • AGN-241622: Allergan (acquired by AbbVie)

And several others.

In conclusion, Presbyopia Market Growth will surge due to market drivers such as an increase in the geriatric population, increasing research in pharmaceutical treatment, and an upsurge in the launch of products; on the other hand, there are a few impediments such as rising healthcare costs, lack of accessibility of eye care services, and shortage of trained ophthalmologists will hamper the growth.

 

Scope of the Presbyopia Market Insight  Report 

  • Geography Covered: 7MM – The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • Presbyopia Markets Segmentation: By Geographies and By Presbyopia Therapies (Historical and Forecasted, Current and Upcoming)
  • Dominant Market Companies investigating its candidates for Presbyopia: Novartis AG, ORASIS Pharmaceuticals Ltd., Eyenovia, AbbVie, Regeneron Pharmaceuticals, Amgen, Ocuphire Pharma, Visus Therapeutics, and others, and several others.
  • Analysis: Comparative and conjoint analysis of emerging therapies.
  • Case Studies
  • KOL’s Views
  • Analyst’s View

 

Table of Contents 

1

Presbyopia Key Insights

2

Presbyopia Report Introduction

3

Presbyopia Market Overview at a Glance

4

Executive Summary of Presbyopia 

5

Presbyopia Market: Future Perspective

6

Presbyopia Epidemiology and Patient Population

7

Presbyopia Disease Background and Overview

8

Presbyopia Diagnosis

9

Early Detection and Prevention of Presbyopia

10

Presbyopia Current Treatment Practices

11

Guidelines of Presbyopia

12

Presbyopia Epidemiology and Patient Population

12.1

The United States

12.2

EU5 Countries

12.2.1

Germany

12.2.2

France

12.2.3

Italy

12.2.4

Spain

12.2.5

The United Kingdom

12.3

Japan

13

Presbyopia Patient Journey

14

Key Endpoints in Presbyopia Clinical Trials

15

Presbyopia Emerging Drugs

15.1

AGN-190584: Allergan (acquired by AbbVie)

15.2

MicroLine (Pilocarpine Ophthalmic): Eyenovia

15.3

PresbiDrops (CSF-1): Orasis Pharmaceuticals

15.4

Nyxol (Phentolamine Mesylate): Ocuphire Pharma

15.5

UNR844 (Lipoic acid choline ester; formerly known as EV06): Novartis

15.6

VTI-001 (Brimochol): Visus Therapeutics

15.7

AGN-241622: Allergan (acquired by AbbVie)

16

Conjoint Analysis of Presbyopia

17

7MM Presbyopia Market Analysis

17.1

The United States Presbyopia Market Size

17.2

EU-5 Presbyopia Market Size

17.2.1

Germany Market Size

17.2.2

France Market Size

17.2.3

Italy Market Size

17.2.4

Spain Market Size

17.2.5

The United Kingdom Market Size

17.3

Japan Presbyopia Market Size

18

Presbyopia Market Access and Reimbursement

19

KOL Views

20

Presbyopia Market Drivers

21

Presbyopia Market Barriers

22

SWOT Analysis of Presbyopia

23

Presbyopia Unmet Needs

24

Appendix

25

DelveInsight Capabilities

26

Disclaimer

27

About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/presbyopia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/goaheadlines.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7